Phase 3 trial progress - The company dosed the first patient in the pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib plus mGnP in first-line metastatic pancreatic cancer.
Favorable Phase 2a data - The company reported 17.3-month median overall survival and a favorable tolerability profile for atebimetinib plus mGnP in first-line pancreatic cancer patients.
Quarterly results and cash position
US oncology drug developer's Q2 net loss beat analyst expectations, and loss per share met consensus.
The company ended Q2 with $182.7 million in cash and equivalents, and said its runway is anticipated into 2029.
Increased R&D expenses were driven by clinical costs for the atebimetinib program.
IMRX•
